prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79 (3-4): 495-500. 26.
1
Pharmacoeconomics 2007; 25 (5): Supplementary Material
ORIGINAL RESEARCH ARTICLE
1170-7690/07/005-0001/$44.95/0 © 2007 Adis Data Information BV. All rights reserved.
Supplementary Material Health Utilities Using the EQ-5D in Studies of Cancer A. Simon Pickard,1,2 Caitlyn T. Wilke,1 Hsiang-Wen Lin1 and Andrew Lloyd3 1 College of Pharmacy, Center for Pharmacoeconomic Research & Departments of Pharmacy Practice and Pharmacy Administration, University of Illinois at Chicago, Chicago, Illinois, USA 2
Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, Illinois, USA
3
United BioSource Corporation, Health Care Analytics Group, London, UK
Supplementary Material This supplementary material contains the figures referred to in the full version of this article, which can be found at http://pharmacoeconomics.adisonline.com
2
Figure 1: Summary of Article Retrieval
Articles Identified by Medline/Embase Search (n = 57) Articles from Authors’ Libraries (n = 7 Articles) Total articles identified by initial search (n = 64)
Full-text articles included for screening (n = 46)
Articles meeting inclusion criteria (n = 34)
Articles reporting EQ-5D scores (n = 31) • Summary index score (n = 26) • Visual analog scale (n = 17) • % problems by dimension (n = 6)
Articles reporting EQ-5D psychometrics (n = 12)
3
Figure 2: Number of cancer-related published studies in the last decade that have reported patients’ HR-QOL using the EQ-5D; data presented according to publication year ((Author: wording ok?)) 8
Number of Studies Published
7
6
5
4
3
2
1
0
1996
1997
Total Reported Studies
1998
1999
2000 2001 2002 Publication Year
EQ-5D Scores Reported
2003
2004
2005
Psychometrics Reported
B BR RE E: :Ba 1s se t d li n ay e, P BR of 3 ret rd re BR E: 3 F atm A BR E: wk C en E 6 p cy t [ BR : 1 mo ost cle 16] E 2 p H [ BR : 1 mo ost DC 16] E: 8 m po HD [1 24 o st C 6] G m pos HD [16 I-L o t C ] IV GI- GI- po HD [1 : B Co Co st C 6] as Re Re HD [16 : G elin : N Sto C [1 ] I-L e o m 6 IV pr St a ] G : P e-s om [20 I-L o ur a ] IV st 1 ge [20 : P /2 ry ] os m [24 t6 o ] m [24 P o ] G RO [24 I-E ] G SO [30 I ] G -ST [4 I-C O 1] G GE oR [4 E G N: N: H e 1] EN P Lo dN [4 : P re- w R k 1] os tre is [41 t- atm k ] tre e [4 at nt 1] m [4 en 3 t[ ] 43 ]
% in each Category
4
Figure 3: Distribution of responses to Mobility dimension of EQ-5D
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
No Problems Some problems Severe problems Any Problems (Some + Severe)
B BR R E E: :Ba 1s se t d lin ay e, P BR of 3 ret r re BR E: 3 d F atm A B R E: wk C en E 6 p cy t [ BR : 1 mo ost cle 16] E 2 p H [ BR : 1 mo ost DC 16] E: 8 m po HD [1 24 o st C 6] G m pos HD [16 I-L o t C ] IV GI- GI- po HD [1 : B Co Co st C 6] as Re Re HD [16 : G elin : N Sto C [1 ] I-L e o m 6 IV pr St a ] G : P e-s om [20 I-L o ur a ] IV st 1 ge [20 : P /2 ry ] os m [24 t6 o ] m [24 PR o [ ] G O 24 I-E ] G SO [30 I ] G -ST [4 I-C O 1] G GE oR [4 E G N: N: H e 1] EN P Lo dN [4 : P re- w R k 1] os tre is [41 t- atm k ] tre e [4 at nt 1] m [4 en 3 t[ ] 43 ] % in each Category
5
Figure 4: Distribution of responses to Self Care dimension of EQ-5D
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
No Problems Some problems Severe problems Any Problems (Some + Severe)
B BR RE E: :Ba 1s se t d lin ay e, P B R of 3 ret r re BR E: 3 d F atm A BR E: wk C en E 6 p cy t [ BR : 1 mo ost cle 16] E 2 p H [ BR : 1 mo ost DC 16] E: 8 m po HD [1 24 o st C 6] G m pos HD [16 I-L o C IV GI- GI- po t H [1 ] D C C : B o o st C 6] as Re Re HD [1 6 G elin : N : St C [ ] I- L e o o m 1 6 IV pr S a ] G : P e-s tom [20 I-L o u a ] IV s t r g e [2 : P 1/2 ry 0] os m [24 t6 o ] m [2 4 P o ] G R O [2 4 I-E ] G S O [3 0 I G -ST [4 ] I- C O 1 ] G GE oR [4 G EN: N: H e 1] EN P Lo d [4 : P re- w Nk 1] os tre Ris [41 t- a t m k ] tre e [4 at nt 1] m [4 en 3 t[ ] 43 ]
% in each Category
6
Figure 5: Distribution of responses to Usual Activities dimension of EQ-5D
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
No Problems Some problems Severe problems Any Problems (Some + Severe)
B BR RE E: :Ba 1 s se t d lin ay e, P BR of 3 ret r re BR E: 3 d F atm A BR E: wk C en 6 p cy t [ E BR : 1 mo ost cle 16] E 2 p H [ BR : 1 mo ost DC 16] E: 8 m po HD [1 24 o st C 6] G m pos HD [16 I-L o t C ] G IV GI- I- po HD [1 C C : B o o st C 6] as Re Re HD [16 : : G elin N Sto C [1 ] I-L e o m 6 IV pr St a ] G : P e-s om [20 I-L o ur a ] IV st 1 ge [20 : P /2 ry ] os m [24 t6 o ] m [24 PR o [ ] G O 24 I-E ] G SO [30 I ] G -ST [4 I-C O 1] oR [4 G GE E G N: N: H e 1] EN P Lo dN [4 : P re- w R k 1] os tre is [41 t- atm k ] tre e [4 at nt 1] m [4 en 3 t[ ] 43 ]
% in each Category
7
Figure 6: Distribution of responses to Pain/Discomfort dimension of EQ-5D
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
No Problems Some problems Severe problems Any Problems (Some + Severe)
B BR RE E: :Ba 1s se t d lin ay e, P BR of 3 ret r re BR E: 3 d F atm A BR E: wk C en E: 6 m po cyc t [1 BR 1 o st le 6] E 2 p H [ BR : 1 mo ost DC 16] E: 8 m po HD [1 24 o st C 6] G m pos HD [16 I-L o t C ] IV GI- GI- po HD [1 : B Co Co st C 6] as Re Re HD [16 : G elin : N Sto C [1 ] I- L e o m 6 IV pr St a ] G : P e-s om [20 I-L o u r a ] IV st 1 ge [20 : P /2 r y ] os m [24 t6 o ] m [24 P o ] G RO [24 I- E ] G SO [30 I ] G -ST [4 I-C O 1] G GE o R [4 E G N: N: H e 1] EN P Lo dN [4 : P re- w R k 1] os tre is [41 t- atm k ] tre e [4 at nt 1] m [4 en 3 t[ ] 43 ]
% in each Category
8
Figure 7: Distribution of responses to Anxiety/Depression dimension of EQ-5D
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
No Problems Some problems Severe problems Any Problems (Some + Severe)
9
References 1. 2. 3.
4.
5.
6. 7. 8. 9. 10. 11. 12.
13.
14.
15. 16.
17.
18. 19.
20.
World Cancer Report. Lyon: IARC Press, 2003 Jemal A, Murphy T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 1030 Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-76. de Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials: the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000; 36 (7): 821-5. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1 (1): 79 Feeny D, Furlong W, Boyle M, Torrance GW. Multiattribute Health-Status Classification Systems: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490-502. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33 (5): 337-43. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 10951108. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002; 11 (4): 341-353. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005; 43 (7): 736-749. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18 (18): 3302-3317 National Institute for Clincal Excellence (UK). Guide to the methods of technology appraisal [online]. Available from URL: http://www.nice.org.uk/page.aspx?0=201973 [Accessed 2007 Apr 17] Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276 (14): 1172-7. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354 (9193): 1896-1900. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177-188. Conner-Spady BL, Cumming C, Nabholtz JM, Jacobs P, Stewart D. A longitudinal prospective study of health-related quality of life in breast cancer patients following highdose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005; 36 (3): 251-9. Jansen SJ, Otten W, van de Velde CJ, Nortier JW, Stiggelbout AM. The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer 2004; 91 (1): 56-61. Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer treatment: impact on health state preferences. Med Care 2002; 40 (11): 1068-79. Verkooijen HM, Buskens E, Peeters PH, Borel Rinkes IH, de Koning HJ, van Vroonhoven TJ. Diagnosing non-palpable breast disease: short-term impact on quality of life of largecore needle biopsy versus open breast biopsy. Surg Oncol 2002; 10 (4): 177-81. Hamashima C. Long-term quality of life of postoperative rectal cancer patients. J Gastroenterol Hepatol 2002; 17 (5): 571-6.
10
21.
22.
23.
24.
25.
26.
27.
28. 29.
30.
31.
32.
33.
34. 35. 36.
37.
Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997; 8 (1): 65-70. Homs MY, Essink-Bot ML, Borsboom GJ, Steyerberg EW, Siersema PD. Quality of life after palliative treatment for oesophageal carcinoma: a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004; 40 (12): 1862-71. Wildi SM, Cox MH, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal Dysphagia. Am J Gastroenterol 2004; 99 (6): 10449. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 2004; 13 (7): 1247-53. McMillan DC, Wigmore SJ, Fearon KC, O’Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79 (3-4): 495-500. O’Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998; 32 (2): 76-80. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005; 75 (2): 116-23 Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin’s disease: a costutility analysis. Eur J Cancer 1996; 32A (9): 1510-7. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin’s lymphoma or Hodgkin’s disease: a prospective randomised trial. Eur J Cancer 2001; 37 (14): 1781-9. Sandblom G, Carlsson P, Sigsjo P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85 (4): 497-503. Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004; 90 (6): 1163-8. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116 (2): 291-6. Bertaccini A, Ceccarelli R, Urbinati M, et al. BSP-PC (Bononian Satisfaction ProfileProstate Cancer): development and validation of a “disease-specific” questionnaire for the evaluation of health-related quality of life in patients with prostate cancer. Arch Ital Urol Androl 2003; 75 (4): 187-94 Lee SH, Kim DJ, Oh JH, Han HS, Yoo KH, Kim HS. Validation of a functional evaluation system in patients with musculoskeletal tumors. Clin Orthop Relat Res 2003; 411: 217-26. van Roijen L, Nijs HG, Avezaat CJ, et al. Costs and effects of microsurgery versus radiosurgery in treating acoustic neuroma. Acta Neurochir (Wien) 1997; 139 (10): 942-8. Uyl-de Groot CA, Buijt I, Gloudemans IJ, Ossenkoppele GJ, Berg HP, Huijgens PC. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005; 74 (2): 136-43. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with nonsmall cell lung cancer: Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19 (8): 855-63.
11
38. 39.
40.
41. 42.
43. 44.
45. 46.
47.
48. 49.
50. 51.
Ananth H, Jones L, King M, Tookman A. The impact of cancer on sexual function: a controlled study. Palliat Med 2003; 17 (2): 202-5 Mantovani G, Madeddu C, Maccio A, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004; 13 (10): 1651-9. Slovacek L, Slovackova B, Jebavy L. Global quality of life in patients who have undergone the hematopoietic stem cell transplantation: finding from transversal and retrospective study. Exp Oncol 2005; 27 (3): 238-242. Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol 2003; 67 (2): 213-20. Norum J. Quality of life (QoL) measurement in economical analysis in cancer: a comparison of the EuroQol questionnaire, a simple QoL-scale and the global QoL measure of the EORTC QLQ-C30. Oncol Rep 1996; 3 (4): 787-791. Weze C, Leathard HL, Grange J, Tiplady P, Stevens G. Evaluation of healing by gentle touch in 35 clients with cancer. Eur J Oncol Nurs 2004; 8 (1): 40-9. Desandes E, Conroy T, Briancon S, et al. Relationship between quality of life and satisfaction with care in patients treated in a Regional Centre Against Cancer. Revue Francophone de Psycho-Oncologie 2005; 4 (1): 29-35. Schneider SM, Pouget I, Staccini P, Rampal P, Hebuterne X. Quality of life in long-term home enteral nutrition patients. Clin Nutr 2000; 19 (1): 23-8. Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 2001; 10 (6): 479-86. Gerard K, Johnston K, Brown J. The role of a pre-scored multi-attribute health classification measure in validating condition-specific health state descriptions. Health Econ 1999; 8 (8): 685-99 Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38 (6): 583-637. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult US population as assessed by the EQ-5D and health utilities index. Med Care 2005; 43 (11): 1078-1086 Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998; 7 (2): 155-166. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000; 38 (1): 115-121
